Type:4 Tablets
Generic Name:Valacyclovir
Manufacturer:Incepta Pharmaceuticals Ltd.
Price:৳300.00
Genital herpes, Herpes zoster, Herpes labialis, CMV infections
May be taken with or without food. May be taken w/ meals to reduce GI discomfort.
Oral Herpes zoster (shingles) Adult: 1 g tid for 7 days. Immunocompromised patients: Continue treatment for a further 2 days after crusting of lesions. Herpes simplex infections of skin and mucous membranes; Genital herpes Adult: 500 mg bid for 3-5 days for recurrent episodes or up to 10 days for initial episodes. Immunocompromised patients: 1 g bid for at least 5 days for recurrent episodes or up to 10 days for initial episodes. Prophylaxis of cytomegaloviral infections in immunocompromised patients Adult: 2 g 4 times daily, begin as soon as possible post-transplant and usually continued for 90 days. Herpes labialis Adult: 2 g 12 hrly for 1 day. Suppression of recurrent herpes simplex Adult: 500 mg daily as a single or in 2 divided doses. Immunocompromised patients: 500 mg bid. Treatment is re-evaluated after 6-12 mth of therapy.
Herpes simplex infections of skin and mucous membranes; Genital herpes Child: >12 yr: 500 mg bid for 3-5 days for recurrent episodes or up to 10 days for initial episodes. Immunocompromised patients: 1 g bid for at least 5 days for recurrent episodes or up to 10 days for initial episodes. Prophylaxis of cytomegaloviral infections in immunocompromised patients Child: >12 yr: 2 g 4 times daily, begin as soon as possible post-transplant and usually continued for 90 days. Herpes labialis Child: >12 yr: 2 g 12 hrly for 1 day. Suppression of recurrent herpes simplex Adult: Child: >12 yr: 500 mg daily as a single or in 2 divided doses. Immunocompromised patients: 500 mg bid. Treatment is re-evaluated after 6-12 mth of therapy. Chickenpox <2 years: Safety and efficacy not established >2 years: 20 mg/kg PO q8hr for 5 days; not to exceed 1 g PO q8hr
Herpes labialis CrCl 30-49 mL/min: 1 g PO q12hr for 1 day CrCl 10-29 mL/min: 500 mg PO q12hr for 1 day CrCl <10 mL/min: 500 mg PO once Herpes zoster CrCl 30-49 mL/min: 1 g PO q12hr CrCl 10-29 mL/min: 1 g/day PO CrCl <10 mL/min: 500 mg/day PO Genital herpes (initial episode) CrCl 10-29 mL/min: 1 g/day PO CrCl <10 mL/min: 500 mg/day PO qDay Genital herpes (recurrent episodes)(suppressive therapy, immunocompetent patients) CrCl <29 mL/min: 500 mg/day PO
Hypersensitvity to valaciclovir, aciclovir.
Valaciclovir is the L-valine ester of aciclovir. A prodrug, it is rapidly converted to aciclovir by intestinal and hepatic metabolism. Aciclovir inhibits DNA synthesis and viral replication and has antiviral activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2) and varicella-zoster virus.
Patient at risk of dehydration. Renal impairment. Pregnancy and lactation. Patient Counselling Avoid sexual intercourse when symptoms of genital herpes are present. Monitoring Parameters Monitor renal, hepatic and haematological functions. Lactation: Drug excreted in breast milk; use with caution
>10% Headache (14-35%),Neutropenia (<18%),Elevated aspartate transaminase (AST) (2-16%),Nasopharyngitis (<16%),Nausea (6-15%),Elevated alanine transaminase (ALT) (<14%),Abdominal pain (2-11%) 1-10% Dysmenorrhea (1-8%),Depression (<7%),Arthralgia (<1-6%),Vomiting (<1-6%),Dizziness (2-4%),Rash (<8%),Rhinorrhea (<2%),Thrombocytopenia (<3%),Leukopenia (<1%) <1% Agitation,Aggression,Alopecia,Confusion,Erythema multiforme,Hypertension,Tachycardia,Tremor,Visual disturbances Potentially Fatal: Hepatitis; renal failure; blood dyscrasias; thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.
Increased risk of renal failure w/ nephrotoxic drugs (e.g. aminoglycosides, organoplatinum compounds, iodinated contrast media, methotrexate, pentamidine, foscarnet, ciclosporin, tacrolimus). Probenecid and cimetidine may increase peak plasma concentrations and AUC of aciclovir.
